CVI performs less well than expected

Adverse currency movements and the integration of Sauflon Pharmaceuticals, the U.K.-based contact lens company, acquired last August, led Cooper Companies to report worse results than previously expected for the fourth quarter ended on Oct. 31, especially for its CooperVision (CVI) subsidiary.

Keep reading this article by becoming a member


Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.